The pharmaceutical industry has spent decades refining drug discovery, biologics manufacturing and fill-finish operations. However, for many combination products today, the greatest risk to launch timelines no longer sits upstream in formulation or production.
BullFrog AI Founder and CEO Vin Singh discusses how the company’s end-to-end AI workflow prepares complex clinical data, identifies disease drivers and patient subgroups, and turns those insights into explainable recommendations designed to improve clinical development decisions.
When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.
For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.
Self-administered drug-device combination products can bring major benefits to clinical trials, improving patient convenience, dosing consistency, compliance, and real-world insight, but they require careful early planning around usability, safety, regulatory requirements, compatibility, manufacturing, and scale-up.
Mark Glass takes a novel approach to serve a patient group, with the ambitious aims of increasing the inclusivity of its existing 1mL safety syringe, simplifying procurement, reducing cost, and reducing carbon footprint.
Carsten Press, one of Vetter’s Managing Directors, discusses the key trends shaping CDMO innovation in today’s dynamic market – and how the family-owned company is integrating these trends into its forward-looking strategy to support consistent quality and seamless drug delivery.
You didn’t get into biotech to become a packaging expert. We did.
Datwyler is a leading provider of high-quality, system-critical elastomer components. We materialize ideas for a safer, smarter and more sustainable world.
Leading Market Positions
As a high-tech company, we focus on pharmaceutical packaging and hold leading positions in attractive global markets such as Healthcare, Mobility, Connectivity, General Industry and Food & Beverage.
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director …
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
August 12 – Lyophilization Manufacturing
August 19 – Excipients
August 26 – Gene Therapy